Gilead signs deals with Indian companies for low-cost HIV drug

Thu Aug 2, 2012 7:19pm IST

Related Topics

Stocks

   

(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.

Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.

Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.

(Reporting by Shailesh Kuber; Editing by Viraj Nair)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

Diabetes And TB

Diabetes And TB

Experts sound alarm as diabetes fuels cases of TB.  Full Article 

Microsoft Band

Microsoft Band

Microsoft launches wearable fitness device for $199.  Full Article 

Long-Term Effect

Long-Term Effect

Having controlling parents may affect later relationships.  Full Article 

Exercise Trend

Exercise Trend

Paddleboard yoga stands venerable practice on its head, on water.  Full Article 

Spike In Polio Cases

Spike In Polio Cases

'Disastrous' health campaign feeds Pakistan's worrying polio spike.  Full Article 

Factbox On GM Crops

Factbox On GM Crops

GMO crops have history of controversy.  Factbox 

Teal Pumpkin Project

Teal Pumpkin Project

Painted pumpkins raising awareness about food allergies.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage